Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: July 2008
-
By Sherri Oslick — Late last week, Judge Pisano of the District Court of New Jersey granted summary judgment of no inequitable conduct in favor of AstraZeneca in its consolidated Paragraph IV litigation against Teva Pharmaceuticals and Sandoz, Inc. over AstraZeneca’s antipsychotic drug Seroquel®. Because the Defendants previously abandoned their other defenses, no…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Shire LLC v. Nostrum Pharmaceuticals, Inc. et al.3:08-cv-03309; filed July 2, 2008 in the District Court of New Jersey Infringement of U.S.…
-
July 7, 2008 – Life After Quanta v. LGE: What Every Patent Lawyer Needs to Know (Practising Law Institute) – 1:00-2:00 PM (EDT) webcast July 9, 2008 – Quanta v. LG: What You Should Know (ALI-ABA) – 12:00-1:00 PM (EST) webcast July 9-11, 2008 – Fundamentals of Patent Prosecution 2008: A Boot Camp for Claim Drafting…
-
Practising Law Institute (PLI) will be offering an audio webcast entitled: "Life After Quanta v. LGE: What Every Patent Lawyer Needs to Know" on July 7, 2008 from 1:00-2:00 PM (EDT). J. Scott Ballenger of Latham & Watkins LLP and Jeffrey T. Green of Sidley Austin LLP will address the following issues: • Can you structure…
-
The Intellectual Property Owners Association (IPO) will be holding its 2008 Annual Meeting on September 21-23, 2008 in San Diego. The meeting will have concurrent patent and trademark sessions. Among the presentations being offered in the patent sessions are: • Overview of Recent Patent Case Law• Indefiniteness Before and After Datamize• The Patent Exhaustion Landscape: …
-
By Donald Zuhn — Last week, the mainstream media turned its attention to the lobbying efforts of biotechnology and pharmaceutical companies. The impetus for this increased coverage was a report on lobbying issued by the Center for Public Integrity (CPI). The CPI, which describes itself as a nonprofit, non-partisan, and non-advocacy organization dedicated…
-
By Kevin E. Noonan — Four Congressman recently stepped into the crisis in world drug pricing, sending a letter to U.S. Trade Representative Susan Schwab last Thursday. The letter, signed by Congressman Charles Rangel (NY-15th Dist.), Congressman Rahm Emanuel (IL-5th Dist.), Congressman Sander Levin (MI-12th Dist.), and Congressman Chris Van Hollen (MD-8th Dist.),…
-
By Donald Zuhn — Last week, the Congressional Budget Office (CBO) released a report on the Biologics Price Competition and Innovation Act (S. 1695), which would establish a pathway for the FDA to approve follow-on biologics. The report was commissioned last summer by the Senate Committee on Health, Education, Labor & Pensions, which…
Patent Docs 